20 years helping business leaders deliver alpha. View our success stories
20 years helping business leaders deliver alpha. View our success stories
By Humatica
As the fall-out from COVID-19 threatens to sink entire portfolios, PE sponsors and CEO’s need to walk a tightrope between preserving organisational capabilities in order to resume growth in case of a rebound in 2H 2020, while at the same time preparing to survive a protracted recession or even depression if things go wrong.
Our latest HumaticaCorner explores the options for portfolio managers and CEOs.
Continuation Funds Surge Continuation fund transactions surged to $63 billion in 2024, driven by a liquidity drought that left 29,000 unsold portfolio companies globally, valued…
Read more
Scaling has become a favorite private equity buzzword. It shows up in nearly every deal thesis, investment committee, and boardroom conversation. Scaling is the fulcrum…
Read more
With a record number of portcos being held and sluggish deal markets, private equity is sharpening its focus on operational resilience. Current macro-economic and geopolitical…
Read more
Erhalten Sie jeden Monat Neuigkeiten und wertvolle Perspektiven zu Themen der organisatorischen Effektivität
